The use of temozolomide for the treatment of malignant tumors: Clinical evidence and molecular mechanisms of action

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 3, 2010, Pages 172-187

  Bei, Roberto ^a   Marzocchella, Laura ^a   Turriziani, Mario ^b  

^a Department of Experimental Medicine and Biochemical Sciences ^*  (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alkylating drug; Anti cancer drug; DNA damage; Temozolomide; Triazenes

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; CISPLATIN; DACARBAZINE; FOTEMUSTINE; IRINOTECAN; LOMEGUATRIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROSOUREA; PEGINTERFERON ALPHA; TEMOZOLOMIDE; THALIDOMIDE; TRIAZENE DERIVATIVE; ALKYLATING AGENT; DRUG DERIVATIVE;

ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ESOPHAGUS CANCER; EWING SARCOMA; EXCISION REPAIR; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; LEIOMYOSARCOMA; LEUKEMIA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MICROCRYSTALLINE SUSPENSION; MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; VOMITING; DRUG COMBINATION; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS;

EID: 78349279248     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210791760526     Document Type: Article

References (206)

1. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
2. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8- carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)- one, a novel broad-spectrum antitumor agent. J Med Chem 1984; 27: 196-201.
3. Lunt, E., Stevens, M.F.G., Stone, R., Wooldridge, K. R. H., Newlands, E. S. Tetrazine derivatives. US5260291 (1993).
4. Palle, R.V., Marathe, A. M., Manda, A. Process for preparing temozolomide. US20070225496 (2007).
5. Wang Y, Stevens MFG, Chan TM, DiBenedetto D, Ding Z-X, Gala D, et al. Antitumor imidazotetrazines. 35. New synthetic routes to the antitumor drug temozolomide. J Org Chem 1997; 62: 7288-94.
6. Etlin, O., Alnabari, M., Sery, Y., Danon, E., Arad, O., Kaspi, J. Process for preparing temozolomide. US20060183898 (2006).
7. Etlin, O., Alnabari, M., Sery, Y., Danon, E., Arad, O., Kaspi, J. Process for preparing temozolomide. US7612202 (2009).
8. Adin, I., Iustain, C. Crystalline forms of temozolomide. US7615632 (2009).
9. Adin, I., Iustain, C. Novel crystalline forms of temozolomide. US20050187206 (2005).
10. Braverman, O., Feinshtein, R., Weisman, A., Kaspi, J. Temozolomide storage system. US20060222792 (2006).
11. Pathi, S. L., Rao, D. R., Kankan, R. N. Process for the preparation of temozolomide and analogs. US20090326028 (2009).
12. Ugwu, S., Radhakrishnan, V., Ihnat, P. M., Witchey-lakshmanan, L. C. Pharmaceutical formulations of antineoplastic agents and processes of making and using the same. US6987108 (2006).
13. Ugwu, S., Radhakrishnan, V., Ihnat, P. M., Witchey-lakshmanan, L. C. Processes of making and using pharmaceutical formulations of antineoplastic agents. US20090176852 (2009).
14. Kuo, S.-C. Synthesis of temozolomide and analogs. US6844434 (2005).
15. Kuo, S.-C., Mas, J. L., Hou, D. Synthesis of temozolomide and analogs.US20020095036 (2002).
16. Kuo, S.-C. Synthesis of temozolomide and analogs. US20020133006 (2002).
17. Kuo, S.-C., Mas, J. L., Hou, D. Synthesis of temozolomide and analogs.US20090023919 (2009).
18. Wang, Y., Conway, B. R., Suppasansatorn, P. Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers. US7173021 (2007).
19. Wang, Y., Conway, B.R., Suppasansatorn, P. Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers. US20060047117 (2006).
20. Wang, Y. Pharmaceutical composition comprising temozolomide ester. US7579336 (2009).
21. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumour drug temozolomide and its interaction with DNA. Biochemistry 1994; 33: 9045-51.
22. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol Res 2007; 56: 275-87.
23. Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 2002; 9: 1285-301.
24. 6-alkylguanine DNA alkyltransferase by antitumor triazene compounds. J Pharmacol Exp Ther 1996; 279: 416-22.
25. Catapano CV, Broggini M, Erba E, Mauro P, Laura M, Lorenzo C, et al. In vitro and in vivo Methazolastone-induced DNA damage and repair in L-l210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 1987; 47: 4884-89.
26. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54: 334-41.
27. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996; 28: 69-85.
28. Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
29. Humbert O, Fiumicino S, Aquilina G, Pauline B, Shinya O, Andrea Z, et al. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis 1999; 20: 205-14.
30. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003; 304: 661-68.
31. 6-alkylguanine-DNA transferases. Mutat Res 1990; 233: 165-75.
32. 6-alkylguanine by alkyltransferases. Mutat Res 2000; 462: 83-100.
33. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993; 67: 1299-1302.
34. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20: 2388-99.
35. Pagani E, Pepponi R, Fuggetta MP, Prete SP, Turriziani M, Bonmassar L, et al. DNA repair enzymes and cytotoxic effects of temozolomide: Comparative studies between tumor cells and normal cells of the immune system. J Chemother 2003; 15: 173-83.
36. Middlemas DS, Stewart CF, Kirstein MN, Catherine P, Henry SF, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6: 99-1007.
37. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 1987; 36: 457-62.
38. D'Atri S, Bonmassar E, Franchi A, Piccioni D, Tuorto V, Del Poeta G, et al. Repair of DNA-methyl adducts and sensitivity to temozolomide of acute myelogenous leukemia (AML) cells. Exper Hematol (NY) 1991; 19: 530-5.
39. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007; 48: 403-7.
40. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumour development, progression, diagnosis, treatment and prognosis. Anticancer Res 2009; 29: 3759-68.
41. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 1992; 13: 1503-7.
42. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. Cancer Res 1991; 51: 4131-4.
43. 6-alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 1985; 76: 2106-14.
44. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol 1995; 23: 112-6.
45. 6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 1992; 3: 401-5.
46. 6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res 2006; 53: 317-23.
47. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000; 85: 248-52.
48. Baer, J. C., Freeman, A. A., Newlands, E.S., Watson, A.J., Rafferty, J. A., Margison, G. P. Potentiation of temozolomide in human tumour cells.US5731304 (1998).
49. 6-alkylguanine-DNA-alkyltransferase. US6303604 (2001).
50. 6-benzyl-8-aza-guanines and 6(4)-benzyloxypyrimidines. US6172070 (2001).
51. 6-benzyl-8-aza-guanines. US6436945 (2002).
52. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 2009; 64: 647-55.
53. Tentori L, Balduzzi A, Portarena I, Levati L, Vernole P, Gold B, et al. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ 2001; 8: 817-28.
54. Tisdale MJ. Antitumour imidazotetrazines-XI: Effect of 8-carbamoyl- 3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism. Br J Cancer 1985; 52: 789-92.
55. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADPribose)n participates in DNA excision repair. Nature (Lond.) 1980; 283: 593-96.
56. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, et al. Potentiation of temozolomide induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995; 72: 849-56.
57. 6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol Carcinog 1991; 4: 482-8.
58. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 1999; 13: 901-9.
59. Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007; 6: 2290-302.
60. Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 2005; 41: 2948-57.
61. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-37.
62. Donawho, C. K., Giranda, V. L. Combination therapy with parp inhibitors. US20080293795 (2008).
63. Donawho, C. K., Giranda, V. L. Combination therapy with parp inhibitors. US20090029966 (2009).
64. Xu, W., Delahanty, G., Wei, L., Zhang, J. Parp inhibitor compounds, compositions and methods of use. US20090098084 (2009).
65. Kalish, V., Zhang, J., Xu, W., Li, J.-H., Xing, A. D., Liu, Q. Compounds, methods and pharmaceutical compositions for inhibiting PARP. US7601719 (2009).
66. Robins, I. H. Treatment of cancer with thymidine in combination with temozolamide. US6642211 (2003).
67. Xu, W., Delahanty, G., Zhang, J. diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP. US20090028815 (2009).
68. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-52.
69. Newlands ES, Blackledge GR, Slack JA, Rustin GJS, Smith DB, Stuart NSA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91.
70. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, et al. Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5: 309-17.
71. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999; 17: 2604-13.
72. Beale P, Judson I, Moore S, Statkevich P, Marco A, Cutler DL, et al. Effect of gastric pH on the relative oral bioavalability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol 1999; 44: 389-94.
73. Riccardi A, Mazzarella G, Cefalo G, Garrè ML, Massimino M, Barone C, et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemother Pharmacol 2003; 52: 459-64.
74. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3: 1093-100.
75. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994; 69: 452-6.
76. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 2004; 15: 161-71.
77. Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C, et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology 2006; 66: 427-9.
78. Zong, C., Winograd, B. Treatment methods. US20060100188 (2006).
79. Zong, C., Winograd, B. Treatment methods. US20090247598 (2009).
80. Argawala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5: 144-51.
81. Ragab, M.H. Cancer treatment with temozolomide. US6346524 (2002).
82. Reidenberg, P., Dugan, M. H. Cancer treatment with temo-zolomide. US5939098 (1999).
83. Bishop, W. R., Kirschmeier, P., Liu, M. Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule. US20090247599 (2009).
84. Bishop, W. R., Kirschmeier, P., Liu, M. Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule. US20070111979 (2007).
85. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-16.
86. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005; 11: 6767-71.
87. Bränström R, Chang YM, Kasparian N, Affleck P, Tibben A, Aspinwall LG, et al. Melanoma risk factors, perceived threat and intentional tanning: An international online survey. Eur J Cancer Prev 2010; 19: 216-26.
88. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
89. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol 2009; 27: 614-25.
90. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
91. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al. Cancer Research Campaign phase II trial of temo-zolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-3.
92. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78: 1199-202.
93. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study. Int J Cancer 2000; 88: 469-73.
94. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003; 21: 821-9.
95. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008; 26: 2299-304.
96. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000; 42: 480-9.
97. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000; 18: 3782-93.
98. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
99. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: A randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 950-7.
100. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21: 2551-7.
101. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002; 20: 2610-5.
102. Whu WJ, Krown SE, Menell JH, Panageas KS, Menell JH, Chapman PB, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21: 3351-6.
103. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: A phase II study Cancer 2005; 103: 2590-7.
104. Hwu, W.J. Compositions and methods for the treatment of cancer. US20020128228 (2002).
105. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005; 23: 9001-7.
106. Hwu WJ, Panageas KS, Menell JH, Lamb La, Aird S, Krown SE, et al. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 2006; 106: 2445-51.
107. Dugan, M.H. Combination therapy (temozolomide and -IFN) for advanced cancer. US7294332 (2007).
108. Zaknoen, S.L. Combination therapy for cancer. US20020009428 (2002).
109. Zaknoen, S. L. Combination therapy for cancer. US20040223951 (2004).
110. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007; 25: 2540-5.
111. Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008; 62: 293-8.
112. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmaco-kinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-36.
113. Friedman, H. S. Methods of using temozolomide in the treatment of cancers.US6251886 (2001).
114. Dugan, M. H. Method for treating pediatric high grade astrocytoma including brain stem glioma. US5942247 (1999).
115. Cutler, D. L. Methods of using temozolomide formulation intrathecally in the treatment of cancers. US20060122162 (2006).
116. Friedman, H. S. Methods of using temozolomide in the treatment of cancers. US6251886 (2001).
117. Duffner PK, Cohen ME, Myers MM, Heise HW. Survival of children with brain tumors: SEER Program 1973-1980. Neurology 1986; 36: 597-601.
118. Brandes AA, Pasetto LM, Vastola F, Monfardini S. Temozolomide in patients with high grade gliomas. Oncology 2000; 59: 181-6.
119. Brandes A, Fiorentino M. The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Invest 1996; 14: 551-9.
120. O'Reilly S, Newlands E, Glaser M, Brampton M, Rice-Edwards JM, Illingworth RD, et al. Temozolomide: Anew oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29: 940-2.
121. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996; 32: 2236-41.
122. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJH, Calvert H, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-8.
123. Baer, J. C., Freeman, A. A., Newlands, E.S., Watson, A.J., Rafferty, J. A., Margison, G. P. Potentiation of temozolomide in human tumour cells. US5731304 (1998).
124. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17: 2762-71.
125. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-7.
126. Brandes AA, Ermani M, Basso U, Amista P, Berti F, Rotilio A, et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. Ann Oncol 2001; 12: 255-7.
127. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-4.
128. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 2009; 11: 281-91.
129. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96: 766-76.
130. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-11.
131. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo dineuro-oncologia (GICNO). Br J Cancer 2006; 95: 1155-60.
132. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008; 89: 179-85.
133. Weller M, Steinbach JP, Wick W. Temozolomide: A milestone in the pharmacotherapy of brain tumors. Future Oncol 2005; 1: 747-54.
134. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23: 2372-7.
135. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
136. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
137. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, et al. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol 2009; 95: 393-400.
138. Houghton, P. J. Combination therapy for cancer. US20030229112 (2003).
139. Adonizio CS, Babb JS, Maiale C, Huang C, Donahue J, Millenson MM, et al. Temozolomide in non-small-cell lung cancer: Preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 2002; 3: 254-8.
140. Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, et al. Temozolomide in patients with advanced nonsmall cell lung cancer with and without brain metastases. A phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39: 1271-6.
141. Somer RA, Langer CJ. Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: Case report. Cancer Invest 2005; 23: 134-7.
142. Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71: 61-5.
143. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Kozloff M, et al. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 245-51.
144. Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 1999; 35: 410-2.
145. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98: 2693-9.
146. Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003; 98: 1942-6.
147. Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005; 98: 99-103.
148. Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, et al. A phase II trial of temozolomide as a 6- week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104: 1706-12.
149. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53: 1029-34.
150. Gavrilovic IT, Posner JB. Brain metastases: Epidemiology and pathophysiology. J Neurooncol 2005; 75: 5-14.
151. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakh S, et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997; 15: 1063-70.
152. Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 1999; 85: 1599-605.
153. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-17.
154. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, et al. Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17: 952-6.
155. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53: 259-65.
156. Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113: 2524-31.
157. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, et al. Phase II study of temozolomide inheavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12: 249-54.
158. Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study. Lung Cancer 2005; 50: 247-54.
159. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 22: 2101-7.
160. Dvorak J, Melichar B, Zizka J, Hadzi-Nikolov D, Petera J. Complete response of multiple melanoma brain metastases after treatment with temozolomide. Onkologie 2004; 27: 171-4.
161. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644-50.
162. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.
163. Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995; 9: 1888-95.
164. Messinger Y, Reaman GH, Ek O, Uckun FM. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia. Leuk Lymphoma 1999; 33: 289-93.
165. Franchi A, Papa G, D'Atri S, Piccioni D, Masi M, Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: A pilot study. Haematologica 1992; 77: 146-50.
166. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002; 20: 3249-53.
167. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells R A, et al. A phase II study of temozolomide therapy for poor-risk patients aged > or = 60 years with acute myeloid leukemia: Low levels of MGMT predict for response. Leukemia 2007; 21: 821-4.
168. Graziani G, Faraoni I, Grohmann U, Bianchi R, Binaglia L, Margison GP, et al. O6-Alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res 1995; 55: 6231-6.
169. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, et al. Chemosensitivity to triazene compounds and O6- alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukemic patients. Ann Oncol 1995; 6: 389-93.
170. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, et al. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995; 7: 224-8.
171. Seiter K, Katragadda S, Ponce D, Rasul M, Ahmed N. Temozolomide and cisplatin in relapsed/refractory acute leucemia. J Hematol Oncol 2009; 2: 21.
172. Dugan, M. H. Combination therapy for advanced cancer. US5824346 (1998).
173. Zong, C., Kirschmeier, P., Medeiros, P. T. Platinum therapeutic combinations. US20060205810 (2006).
174. Caporaso P, Turriziani M, Venditti A, Marchesi F, Buccisano F, Tirindelli MC, et al. Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. DNA Repair (Amst) 2007; 6: 1179-86.
175. Horning SJ. Treatment approaches to the low-grade lymphomas. Bloods 1994; 83: 881-4.
176. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15 2002. J Clin Oncol 2003; 21: 2407-14.
177. Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer 2004; 40: 1682-8.
178. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96: 864-7.
179. Lerro KA, Lacy J. Case report: A patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 2002; 59: 165-8.
180. Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J. Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma-case report. Neurol Med Chir (Tokyo) 2007; 47(5): 229-32.
181. Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, et al. Primary CNS lymphoma in the elderly: Temozolomide therapy and MGMT status. J Neurooncol 2009 Oct 20. [Epub ahead of print].
182. Woll PJ, Crowther D, Johnson PWM, Soukop M, Harper PG, Harris M, et al. Phase H trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 1995; 72: 183-4.
183. Tani M, Fina M, Alinari L, Stefoni V, Baccarani M, Zinzani PL. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica 2005; 90: 1283-4.
184. Orlow, S. J., Chen, M. Methods and compositions for the treatment of cancers, such as melanomas and gliomas. US20090270397 (2009).
185. Dukart, G., Gibbons Jr., J. J. Antineoplastic combinations. US20060030547 (2006).
186. Gerson, S.L., Liu, L. Methoxyamine combinations in the treatment of cancer. US20020198264 (2002).
187. Mcmurry, T. B. H., Mcelhinney, R. S., Donnelly, D. J., Murray, P., Carola, C., Elder, R., Kelly, J., Margison, G. P., Rafferty, J. A., Watson, A. J., Willington, M. A. Pyrimidine and purine derivatives and their use in treating tumour cells. US5929046 (1999).
188. Schwendner, S., Timmermans, P., Walling, J. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents. US6822001 (2004).
189. Rudy, S., Amtmann, E. 2-Methylthiazolidine-2, 4-dicarboxylic acid-containing combination preparations. US20070213382 (2007).
190. Cleland, J. L., Wong, A., Lalani, A S. Treatment of hyperproliferative diseases with anthraquinones. US20070117784 (2007).
191. Martin, N. M. B., Smith, G. C. M., Eversley, P. J., Cockcroft, X-l., Kerrigan, F., Hoare, Janet, Dixon, L. Phthalazinone derivatives. US7196085 (2007).
192. Becker, R.P., Johri, A.R., Mcsheehy, P.M.J., Zaknoen, S. Epothilone combinations. US20090041715 (2009).
193. Dugan, M.H. Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor. US20060211674 (2006).
194. Sobol, R.W. Inhibiting dna polymerase beta to enhance efficacy of anticancer agents. US20090081119 (2009).
195. Bishop, W.R., Catino, J.J., Doll, R.J., Ganguly, A., Girijavallabhan, V. M., Kirschimeier, P., Liu, M., Nielsen, L.L., Cutler, D.L. Methods for treating proliferative diseases. US6333333 (2001).
196. Bishop, W. R., Brassard, D. L., Nagabhushan, T. L. Methods of inducing cancer cell death and tumor regression. US6316462 (2001).
197. Sampson, J. H., Bigner, D. D., Duane, M., Heimberger, A. Concurrent chemotherapy and immunotherapy. US20090220551 (2009).
198. Schlingensiepen, K-H., Schlinensiepen, R. Pharmaceutical composition. US20070196269 (2007).
199. Pickett, C. B., Bishop, W. R., Wang, Y. Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor. US20070112053 (2007).
200. Zeldis, J. B. Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline. US7323479 (2008).
201. Bigner, D.D., Zalutsky, M. Combination therapy in the treatment of cancer. US20060257317 (2006).
202. Goodman, S., Picard, M. A., Mikkelsen, T., Nippgen, J., Grimm, U., Stupp, R., Weller, M., Harstrick, A., Grell, M. Specific therapy using integrin ligands for treating cancer. US20090130098 (2009).
203. Goydos, J.S., Chen, S. Methods and compositions for treating melanoma. US20080124333 (2008).
204. Srivastava, P. K., Li, Z. Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality. US20090208524 (2009).
205. Johnson, W. W., Wang, E., Casciano, C., Clement, R. P. Methods for treating multidrug resistance. US6703400 (2004).
206. Van Tellingen, O. Methods and means for the treatment of cancer. US20090170880 (2009).